Downregulation of EIF4G2 could induce reacquisition of chemosensitivity to paclitaxel in ovarian cancer [29] and enhance cisplatin chemosensitivity in nonsmall cell lung cancer [30]. Here, EIF4G2 is linked to ovarian cancer.